These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3742466)

  • 1. The significance of the fibrin/fibrinogen degradation product in serum of carcinoma patients with hematogenous metastasis.
    Imaoka S; Sasaki Y; Iwanaga T; Terasawa T
    Cancer; 1986 Oct; 58(7):1488-92. PubMed ID: 3742466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody.
    Koopman J; Haverkate F; Koppert P; Nieuwenhuizen W; Brommer EJ; Van der Werf WG
    J Lab Clin Med; 1987 Jan; 109(1):75-84. PubMed ID: 3540164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of FDP-E analysis in blood coagulation and fibrinolysis tests].
    Horiuchi N; Aoki Y; Terada H
    Nihon Rinsho; 1989 Dec; 48 Suppl():896-900. PubMed ID: 2622026
    [No Abstract]   [Full Text] [Related]  

  • 4. [Fibrin/fibrinogen degradation products (FDP)].
    Kuroso K; Fujimaki M
    Nihon Rinsho; 1989 Dec; 48 Suppl():892-5. PubMed ID: 2622025
    [No Abstract]   [Full Text] [Related]  

  • 5. [Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma].
    Mischke R; Wohlsein P; Busse L; Pohlenz J
    Schweiz Arch Tierheilkd; 1998; 140(12):497-505. PubMed ID: 9863356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and clinical significance of elevated fibrin(ogen) degradation product and/or D-dimer levels in liver cirrhosis patients.
    Cioni G; Cristani A; Mussini C; Grandi S; Pentore R; Zeneroli ML; Tizzanini W; Zagni G; Ventura E
    Ital J Gastroenterol; 1990 Apr; 22(2):70-4. PubMed ID: 2131934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High fibrin/fibrinogen degradation product to fibrinogen ratio is associated with 28-day mortality and massive transfusion in severe trauma.
    Lee DH; Lee BK; Noh SM; Cho YS
    Eur J Trauma Emerg Surg; 2018 Apr; 44(2):291-298. PubMed ID: 28921171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Studies on the fragments of FDP in 3 patients with DIC associated with acute promyelocytic leukemia].
    Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Nakahata T; Saitoh H
    Rinsho Byori; 1993 Jun; 41(6):719-25. PubMed ID: 8361040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of plasma fibrin D-dimer levels with the use of a monoclonal antibody coupled to latex beads.
    Greenberg CS; Devine DV; McCrae KM
    Am J Clin Pathol; 1987 Jan; 87(1):94-100. PubMed ID: 3541576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hemostatic changes before and after the onset of disseminated intravascular coagulation].
    Wada H; Tanigawa M; Takagi M; Suzuki H; Mori Y; Ohta T; Kobayashi T; Kita K; Tanaka I; Yamaguchi T
    Rinsho Ketsueki; 1989 Oct; 30(10):1755-62. PubMed ID: 2593241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the fibrinolytic state by measuring stable cross-linked fibrin degradation products in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
    Okajima K; Koga S; Okabe H; Inoue M; Takatsuki K
    Acta Haematol; 1989; 81(1):15-8. PubMed ID: 2494830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation.
    Lane DA; Preston FE; VanRoss ME; Kakkar VV
    Br J Haematol; 1978 Dec; 40(4):609-15. PubMed ID: 365218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative study of various rapid methods of determining fibrinogen transformation products in the diagnosis of intravascular coagulation and fibrinolysis].
    Lychev VG; Momot AP; Cherkashin GV
    Ter Arkh; 1984; 56(6):106-9. PubMed ID: 6474366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Problems of diagnosis of disseminated intravascular coagulation (DIC).
    Bowie EJ; Owen CA
    Southeast Asian J Trop Med Public Health; 1979 Sep; 10(3):325-7. PubMed ID: 515796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical significance of fibrinogen degradation products.
    Bick RL
    Semin Thromb Hemost; 1982 Oct; 8(4):302-30. PubMed ID: 6758120
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum crosslinked fibrin (XDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems.
    Hunt FA; Rylatt DB; Hart RA; Bundesen PG
    Br J Haematol; 1985 Aug; 60(4):715-22. PubMed ID: 3896298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis.
    Ambrus JL; Ambrus CM; Pickern J; Soldes S; Bross I
    J Med; 1975; 6(5-6):433-58. PubMed ID: 130433
    [No Abstract]   [Full Text] [Related]  

  • 18. Higher prognostic value of soluble fibrin complexes than D-dimer and fibrin degradation product for disseminated intravascular coagulation in patients with liver cirrhosis.
    Kim SY; Kim JE; Kim HK; Kim I; Yoon SS; Park S
    Blood Coagul Fibrinolysis; 2013 Mar; 24(2):150-6. PubMed ID: 23314386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disseminated intravascular coagulation in prostatic disease.
    Deutsch E
    Prog Clin Biol Res; 1976; 6():313-27. PubMed ID: 66693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinction between fibrinogen and fibrin degradation products produced during disseminated intravascular coagulation in childhood.
    Yoshioka K; Mizuno S; Miyata H; Maki S
    Eur J Pediatr; 1982 Feb; 138(1):46-8. PubMed ID: 7075627
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.